title: Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer.
abstract: Adjuvant endocrine therapy for breast cancer reduces recurrence and improves survival rates. Many patients never start treatment or discontinue prematurely. A better understanding of factors associated with endocrine therapy initiation and persistence could inform practitioners how to support patients. We analyzed data from a longitudinal study of 2,268 women diagnosed with breast cancer and reported to the Metropolitan Detroit and Los Angeles SEER cancer registries in 2005-2007. Patients were surveyed approximately both 9 months and 4 years after diagnosis. At the 4-year mark, patients were asked if they had initiated endocrine therapy, terminated therapy, or were currently taking therapy (defined as persistence). Multivariable logistic regression models examined factors associated with initiation and persistence. Of the 743 patients eligible for endocrine therapy, 80 (10.8 %) never initiated therapy, 112 (15.1 %) started therapy but discontinued prematurely, and 551 (74.2 %) continued use at the second time point. Compared with whites, Latinas (OR 2.80, 95 % CI 1.08-7.23) and black women (OR 3.63, 95 % CI 1.22-10.78) were more likely to initiate therapy. Other factors associated with initiation included worry about recurrence (OR 3.54, 95 % CI 1.31-9.56) and inadequate information about side effects (OR 0.24, 95 % CI 0.10-0.55). Factors associated with persistence included two or more medications taken weekly (OR 4.19, 95 % CI 2.28-7.68) and increased age (OR 0.98, 95 % CI 0.95-0.99). Enhanced patient education about potential side effects and the effectiveness of adjuvant endocrine therapy in improving outcomes may improve initiation and persistence rates and optimize breast cancer survival.
authors.affiliation: University of Michigan, 400 North Ingalls #4162, Ann Arbor, MI, USA. cfriese@umich.edu
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Friese
authors.forename: T May
authors.initials: TM
authors.lastname: Pini
authors.forename: Yun
authors.initials: Y
authors.lastname: Li
authors.forename: Paul H
authors.initials: PH
authors.lastname: Abrahamse
authors.forename: John J
authors.initials: JJ
authors.lastname: Graff
authors.forename: Ann S
authors.initials: AS
authors.lastname: Hamilton
authors.forename: Reshma
authors.initials: R
authors.lastname: Jagsi
authors.forename: Nancy K
authors.initials: NK
authors.lastname: Janz
authors.forename: Sarah T
authors.initials: ST
authors.lastname: Hawley
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Katz
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Griggs
mesh_terms: D000328:Adult; D001741:Black or African American; D000368:Aged; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*; D017024:Chemotherapy, Adjuvant / Q000706:statistics & numerical data; D005260:Female; D006630:Hispanic or Latino; D006801:Humans; D016015:Logistic Models; D008137:Longitudinal Studies; D015141:Los Angeles / Q000453:epidemiology; D008824:Michigan / Q000453:epidemiology; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control / Q000523:psychology; D018426:SEER Program; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D044465:White People; D055815:Young Adult
chemical_list: D047072:Aromatase Inhibitors; D020845:Selective Estrogen Receptor Modulators
references.citation: Oncology. 2006;71(1-2):1-9
references.pmid: 17344666
references.citation: J Clin Oncol. 2003 Feb 15;21(4):602-6
references.pmid: 12586795
references.citation: J Natl Cancer Inst. 2002 Nov 6;94(21):1626-34
references.pmid: 12419789
references.citation: Breast Cancer Res Treat. 2012 May;133(1):285-96
references.pmid: 22278190
references.citation: J Clin Oncol. 2012 Sep 1;30(25):3058-64
references.pmid: 22869890
references.citation: J Clin Oncol. 1999 May;17(5):1458-64
references.pmid: 10334531
references.citation: Cancer Prev Res (Phila). 2011 Sep;4(9):1360-5
references.pmid: 21893499
references.citation: J Psychosom Res. 1999 Dec;47(6):555-67
references.pmid: 10661603
references.citation: Am J Manag Care. 2004 Nov;10(11 Pt 2):861-8
references.pmid: 15609740
references.citation: J Clin Oncol. 2006 Feb 20;24(6):872-7
references.pmid: 16484696
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2276-81
references.pmid: 12805326
references.citation: J Clin Oncol. 2009 Jul 20;27(21):3445-51
references.pmid: 19451445
references.citation: J Clin Oncol. 2003 Sep 1;21(17):3357-65
references.pmid: 12847142
references.citation: J Clin Oncol. 2012 Jan 10;30(2):142-50
references.pmid: 22147735
references.citation: Patient Educ Couns. 2005 Oct;59(1):97-102
references.pmid: 16198223
references.citation: Breast Cancer Res Treat. 2008 Sep;111(2):365-72
references.pmid: 17922185
references.citation: Lancet Oncol. 2006 Aug;7(8):633-43
references.pmid: 16887480
references.citation: J Natl Cancer Inst. 2012 Jul 18;104(14):1102-5
references.pmid: 22773822
references.citation: Breast Cancer Res Treat. 2011 Apr;126(2):529-37
references.pmid: 20803066
references.citation: J Natl Cancer Inst. 1996 Nov 6;88(21):1543-9
references.pmid: 8901852
references.citation: J Clin Oncol. 2012 Mar 1;30(7):718-21
references.pmid: 22042967
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2022-9
references.pmid: 19549806
references.citation: Cancer Prev Res (Phila). 2011 Sep;4(9):1393-400
references.pmid: 21862698
references.citation: J Clin Oncol. 2008 Feb 1;26(4):549-55
references.pmid: 18071188
references.citation: J Clin Oncol. 2004 Aug 15;22(16):3309-15
references.pmid: 15310774
references.citation: Lancet Oncol. 2008 Jan;9(1):45-53
references.pmid: 18083636
references.citation: Breast Cancer Res Treat. 2006 Sep;99(2):215-20
references.pmid: 16541307
references.citation: BMC Cancer. 2012 Oct 15;12:474
references.pmid: 23066928
references.citation: Cancer. 2000 Oct 15;89(8):1739-47
references.pmid: 11042569
references.citation: J Am Coll Surg. 2008 Jan;206(1):66-75
references.pmid: 18155570
references.citation: Circulation. 2009 Jan 27;119(3):390-7
references.pmid: 19139387
references.citation: Med Care. 2007 May;45(5):431-9
references.pmid: 17446829
references.citation: Breast Cancer Res Treat. 2012 May;133(1):297-9
references.pmid: 22399189
references.citation: J Oncol Pharm Pract. 2013 Jun;19(2):105-10
references.pmid: 22895656
references.citation: J Clin Oncol. 2001 Jan 15;19(2):322-8
references.pmid: 11208822
references.citation: Am J Clin Oncol. 2013 Apr;36(2):181-7
references.pmid: 22314001
references.citation: Health Educ Q. 1984 Spring;11(1):1-47
references.pmid: 6392204
references.citation: Arch Intern Med. 2005 Aug 8-22;165(15):1749-55
references.pmid: 16087823
references.citation: Breast Cancer. 2001;8(4):294-7
references.pmid: 11791120
references.citation: J Clin Oncol. 2008 Feb 1;26(4):556-62
references.pmid: 18180462
references.citation: Eur J Cancer. 2006 Sep;42(14):2271-6
references.pmid: 16644208
references.citation: N Engl J Med. 2005 Aug 4;353(5):487-97
references.pmid: 16079372
references.citation: Cancer. 2011 May 1;117(9):1827-36
references.pmid: 21445916
references.citation: Cancer. 2011 Jan 15;117(2):398-405
references.pmid: 20824718
references.citation: Med Care. 2004 Mar;42(3):200-9
references.pmid: 15076819